Novo Nordisk Invests $4.1 Billion For New US Facility—Boosting Ozempic Production
Novo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company's weight loss and diabetes drugs Wegovy and Ozempic, the Danish firm said Monday.
Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing
Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on Monday.
Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic
Novo Nordisk said it will spend $4.1 billion to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. The investment will fund a new manufacturing plant in Clayton, North Carolina, responsible for filling and packaging syringes and injection pens for the drugs.
Teva launches generic version of Novo Nordisk's diabetes drug Victoza
Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.
Nestle launches 'Ozempic face' range as sales of weight-loss drugs soar
Swiss consumer products giant Nestle S.A. (OTC:NSRGF, VTX:NESN)is introducing to help disguise the effect of rapid weight loss brought by the use of drugs such as Novo Nordisk (NYSE:NVO)'s Ozempic and Wegovy and Eli Lily's Mounjaro Nestle is bracing itself for a slump in sales of staples such as KitKat and Smarties due to the demand for weight-loss products, but is not sitting still with the new product lines to counteract the effect known as ‘Ozepmic face”.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo's Wegovy induces higher weight loss in women than men with same heart condition, study shows
Novo Nordisk's popular obesity drug Wegovy helped women with a common heart disease lose more weight than men who had the same condition, an analysis of study data published in a medical journal has shown.
The Best Could Be Yet to Come for Novo Nordisk and Ozempic
Novo Nordisk's top-two blockbuster drugs include the same active ingredient -- semaglutide. The company is testing an even higher-dose version of semaglutide, which may yield even better results.
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
Novo Nordisk (NVO) closed the most recent trading day at $142.50, moving +0.01% from the previous trading session.
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
The Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
